

2019 Aranesp® (darbepoetin alfa) Prior Authorization Request

Page 1 of 3

(You must complete all 3 pages.)

Fax completed form to: 1-800-408-2386

For urgent requests, please call: 1-800-414-2386

Patient information		Prescriber information		
Patient name	Today's date		Physician specialty	
Patient insurance ID number	Physician name		NPI/DEA number	
Patient address, city, state, ZIP		Physician address, city, state, ZIP		
Patient home telephone number		M.D. office telephone number		
Gender <input type="checkbox"/> Male <input type="checkbox"/> Female	Patient date of birth	M.D. office fax number		
Diagnosis and medical information				
Medication requested <input type="checkbox"/> Aranesp	Diagnosis <input type="checkbox"/> Anemia due to chronic kidney disease (CKD) <input type="checkbox"/> Anemia due to end stage renal disease (ESRD) with DIALYSIS <input type="checkbox"/> Anemia due to myelosuppressive anticancer chemotherapy in patients with non-myeloid malignancies <input type="checkbox"/> Other diagnosis/(ICD10): _____			
Strength and route of administration	Quantity	Day supply	Expected length of therapy	
Please check all boxes that apply:				
<input type="checkbox"/> New start <input type="checkbox"/> Restart <input type="checkbox"/> Renewal				
1. Where is medication being administered? <input type="checkbox"/> Patient's home (self-administered) <input type="checkbox"/> Office administered (office supplies drug) / J CODE: _____ <input type="checkbox"/> Office administered (pharmacy supplies drug) <input type="checkbox"/> Dialysis center				
2. <input type="checkbox"/> Has the member tried and failed Procrit® (erythropoietin injection) or does the member have a contraindication or intolerance to Procrit? <input type="checkbox"/> All covered Part D drugs on any tier of the plan's formulary would not be as effective for the enrollee as the requested formulary drug and/or would likely have adverse effects for the enrollee.				
3. <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient on dialysis? If yes, please answer the following: <input type="checkbox"/> Yes <input type="checkbox"/> No Does the prescriber (i.e. nephrologist, nurse practitioner, or physician assistant) receive a monthly capitation payment to manage ESRD patients' care? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the Aranesp to be used for an ESRD-related condition?				

(continued on page 2)

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. **If you received this transmission in error, please notify us immediately by telephone at 1-800-414-2386.**

Please check all boxes that apply (continued):

4. For NEW STARTS, please complete this section.

- Yes No **Does the patient meet one of the following criteria?**
 - ▶ Adequate iron stores have been demonstrated by means of bone marrow iron or serum ferritin levels or serum iron saturation studies within the prior 12 months, or
 - ▶ Patient has iron deficiency, but erythropoietin analog therapy will be initiated simultaneously with iron replacement
- Yes No **Is Aranesp requested for the treatment of anemia due to chronic kidney disease in a patient NOT on dialysis and does the patient have a hemoglobin (Hgb) level that is approaching or has fallen below 10 g/dl OR a hematocrit of 30% or less?**
- Yes No **Is Aranesp requested for the treatment of anemia due to chronic kidney disease in a patient who IS currently on dialysis and does the patient have a hemoglobin (Hgb) level that is approaching or has fallen below 11 g/dl OR a hematocrit of 30% or less?**
- Yes No **Is Aranesp requested for the treatment of anemia due to chronic kidney disease in a PEDIATRIC patient and does the patient have a hemoglobin (Hgb) level that is approaching or has fallen below 12 g/dl OR a hematocrit of 30% or less?**
- Yes No **Is Aranesp requested for the treatment of anemia due to the start of myelosuppressive anticancer chemotherapy and the patient will have an anticipated hemoglobin (Hgb) drop associated with the therapy?**

Please complete this section below only if your patient does not meet the standard requirements listed above.

Please explain why your patient should be considered for exception although not meeting the plan's suggested PA criteria. Statement should include specifically which requirement is not met and why patient should be exempt from meeting this requirement. (Please note any information that is incomplete or illegible will delay the review process.)

5. For RENEWALS, please complete this section.

- Yes No **Did the patient have an Hgb rise of LESS THAN 1 g/dl (or hematocrit rise LESS THAN 3%) compared to pretreatment baseline by 12 weeks of treatment and an Hgb level that remained LESS THAN 10 g/dl (or hematocrit LESS THAN 30%)?**
- Yes No **Is Aranesp therapy being administered to an Hgb target of 12 g/dl for anemia due to myelosuppressive anticancer chemotherapy?**
- Yes No **Is Aranesp therapy being administered to an Hgb target of 10-11 g/dl for patients with chronic renal failure and end-stage renal disease?**

Please complete this section below only if your patient does not meet the standard requirements listed above.

Please explain why your patient should be considered for exception although not meeting the plan's suggested PA criteria. Statement should include specifically which requirement is not met and why patient should be exempt from meeting this requirement. (Please note any information that is incomplete or illegible will delay the review process.)

(continued on page 3)

Please check all boxes that apply (continued):

6. Yes No **Aranesp is not covered for patients with Hgb at or above 10 g/dl (CKD not on dialysis-adult, cancer), 11 g/dl (CKD on dialysis) and 12 g/dl (pediatric CKD) or patients with uncontrolled hypertension, due to serious adverse effects. Does patient have Hgb at or above 10 g/dl (CKD not on dialysis-adult, cancer), 11 g/dl (CKD on dialysis), 12 g/dl (pediatric CKD) or uncontrolled hypertension?**

7. **Other supporting information:**

*NOTE: All exception requests require prescriber supporting statements. Additionally, requests that are subject to prior authorization (or any other utilization management requirement), may require supporting information. Please attach supporting information, as necessary, for your request.

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that documentation supporting this information is available for review if requested by the health plan sponsor, or, if applicable, a state or federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS.

Prescriber signature

Date